09:28 AM EST, 02/18/2025 (MT Newswires) -- Nexalin Technology ( NXL ) said Tuesday that the University of California in San Diego Institutional Review Board has approved the use of its Halo Clarity headset in human subjects in clinical trials.

The headsets will be tested in clinical trials to assess their efficacy in treating mild traumatic brain injury and post-traumatic stress disorder, particularly in military personnel, the company said.

The company and its manufacturing partner have begun preparing the initial shipment of 50 headsets to the university, which is conducting the study independently, Nexalin ( NXL ) said.

Nexalin ( NXL ) said the headset is a non-invasive treatment that can be used at home and allows physicians to monitor patient progress remotely.